Orexigen hoping for quicker resubmission path for weight-loss drug
This article was originally published in Scrip
Chomping at the bit to get into the horse race in the antiobesity market – with the US FDA already approving two new drugs in recent months to treat the condition, Vivus' Qsymia (phentermine and topiramate) and Arena Pharmaceuticals' and Eisai's Belviq (lorcaserin) – Orexigen Therapeutics gave investors new hope its experimental medicine Contrave (naltrexone/bupropion) may have a quicker path to the finish line than earlier thought.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.